Skip to main content
CivicGate

HR 7391
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

Community Health Center Drug Pricing Protection Act

To amend title III of the Public Health Service Act to ensure that Federally-qualified health centers are not required to pay more than the 340B ceiling price for covered outpatient drugs at the time of purchase.

Introduced Feb 5, 2026

Latest action (Feb 5, 2026) Referred to the House Committee on Energy and Commerce.

Referred to
Energy and Commerce Committee
Policy area
Health
Issues
Healthcare

Summary

The Community Health Center Drug Pricing Protection Act amends the 340B Drug Pricing Program to require pharmaceutical manufacturers to provide the full discount (ceiling price) on covered drugs at the time of purchase by federally-qualified health centers, rather than through later rebates or reconciliation. Currently, some manufacturers charge more upfront and then provide rebates or reimbursements later; this bill prohibits that practice for federally-qualified health centers. The provision takes effect immediately upon enactment and applies to drugs purchased after enactment, as well as to existing manufacturer agreements going forward. This ensures federally-qualified health centers receive the negotiated discount price upfront rather than having to pay higher prices initially with adjustments later.

AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.

Sponsor (1)
54 cosponsors

Actions (2)
  1. Feb 5, 2026 Referred to the House Committee on Energy and Commerce. · house
  2. Feb 5, 2026 Introduced in House

Similar bills (6)

Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.

  • HR 9040 — Regulate the Price of All Drugs Act · Introduced May 26, 2026 · Cong. 119 75%
  • HR 6166 — Lowering Drug Costs for American Families Act · Introduced Nov 20, 2025 · Cong. 119 74%
  • HR 7871 — MVP Act · Introduced Mar 9, 2026 · Cong. 119 72%
  • HR 9599 — SECURE 340B Act · Introduced Jul 6, 2026 · Cong. 119 71%
  • S 909 — Prescription Drug Price Relief Act of 2021 · Introduced Mar 23, 2021 · Cong. 117 70%
  • HR 3546 — Prescription Drug Price Relief Act of 2025 · Introduced May 21, 2025 · Cong. 119 70%

Full text

IN THE HOUSE OF REPRESENTATIVES

February 5, 2026

Mr. Bergman (for himself, Mr. Auchincloss, Mr. Moulton, Mr. Lynch, Mr. Smucker, Ms. Lois Frankel of Florida, Ms. Norton, Mr. Mann, Mr. Mrvan, Ms. Balint, Ms. Davids of Kansas, Ms. Maloy, Mr. Bresnahan, Mr. Cleaver, Ms. Ansari, Mr. Huizenga, Ms. McBride, Ms. Titus, Ms. Tlaib, Mr. Neguse, Mr. Crank, Ms. Lee of Nevada, Mr. Lucas, Mr. Larsen of Washington, and Mr. Cohen) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend title III of the Public Health Service Act to ensure that Federally-qualified health centers are not required to pay more than the 340B ceiling price for covered outpatient drugs at the time of purchase.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Community Health Center Drug Pricing Protection Act”.

SEC. 2. ENSURING UPFRONT 340B DISCOUNTED PRICING FOR FEDERALLY- QUALIFIED HEALTH CENTERS.

(a) In General.—Section 340B(a) of the Public Health Service Act (42 U.S.C. 256b(a)) is amended by adding at the end the following new paragraph:

“(11) Upfront discounted pricing for federally-qualified health centers.—The Secretary may not enter into an agreement with a manufacturer of covered outpatient drugs under paragraph

(1) under which the amount required to be paid to the manufacturer for covered outpatient drugs by a covered entity described in paragraph (4)(A) exceeds, at the point of purchase of such drug, the applicable ceiling price for such drug (as described in paragraph (1)).”.

(b) Rule of Construction.—Nothing in this section, or the amendment made by this section, shall be construed to permit under paragraph (1) of section 340B(a) of the Public Health Service Act (42 U.S.C. 256b(a)) any arrangement under which a covered entity described in paragraph (4)(A) of such section pays to the manufacturer of a covered outpatient drug an amount in excess of the applicable ceiling price for such drug (as described in such paragraph (1)) at the time of purchase, with later reconciliation by rebate, reimbursement, or other payment.

(c) Effective Dates.—

(1) In general.—The amendments made by this section shall take effect on the date of the enactment of this section and shall apply to drugs purchased on or after the date of the enactment of this section.

(2) Application to existing agreements.—Beginning on the date of the enactment of this section, the amendments made by this section shall be taken into account in determining whether an agreement with a manufacturer of covered outpatient drugs meets the requirements of section 340B(a) of the Public Health Service Act (42 U.S.C. 256b(a)). <all>

Comments

Comments

Loading comments…